RT Journal Article
SR Electronic
T1 Predictive Factors of Nivolumab-induced Hypothyroidism in Patients with Non-small Cell Lung Cancer
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 1035
OP 1039
VO 31
IS 5
A1 MAEKURA, TOSHIYA
A1 NAITO, MAIKO
A1 TAHARA, MASAHIRO
A1 IKEGAMI, NAOYA
A1 KIMURA, YOHEI
A1 SONOBE, SHOKO
A1 KOBAYASHI, TAKEHIKO
A1 TSUJI, TAISUKE
A1 MINOMO, SHOJIRO
A1 TAMIYA, AKIHIRO
A1 ATAGI, SHINJI
YR 2017
UL http://iv.iiarjournals.org/content/31/5/1035.abstract
AB Background/Aim: Although immune checkpoint inhibitors play an important role in the therapy of lung cancer, they are associated with various immune-related adverse events and predictive factors of them are unclear. In this study, we investigated predictive factors of nivolumab-induced hypothyroidism which is one of the adverse events in patients with lung cancer. Patients and Methods: Patients with non-small-cell lung cancer who were administered nivolumab at our hospital between December 2015 and May 2016 were retrospectively enrolled. The thyroid-stimulating hormone, free triiodothyronine, free thyroxine, thyroid peroxidase (TPO) antibody, and thyroglobulin antibody levels of each patient were analyzed. Results: Of the 64 patients enrolled, 5 (7.8%) developed hypothyroidism after treatment with nivolumab. The TPO and thyroglobulin antibodies were significantly positive in patients who developed primary hypothyroidism. Conclusion: TPO and thyroglobulin antibody levels at baseline may be predictive of hypothyroidism.